Digging into lorlatinib resistance in ALK-positive lung cancer: an editorial

Chin Clin Oncol. 2019 Oct;8(S1):S2. doi: 10.21037/cco.2018.09.04. Epub 2018 Oct 10.

Authors

Francesco Facchinetti¹, Marcello Tiseo²

Affiliations

¹ INSERM U981, Gustave Roussy Cancer Campus, Université Paris Saclay, Villejuif, France; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
² Medical Oncology Unit, University Hospital of Parma, Parma, Italy. mtiseo@ao.pr.it.

PMID: 30525750
DOI: 10.21037/cco.2018.09.04

No abstract available

Publication types

Editorial

MeSH terms

Aminopyridines
Humans
Lactams
Lactams, Macrocyclic / pharmacology
Lactams, Macrocyclic / therapeutic use*
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Pyrazoles

Substances

Aminopyridines
Lactams
Lactams, Macrocyclic
Pyrazoles
lorlatinib